Abstracts tagged "biomarkers and nephritis"

Abstract Number: 2850 • 2016 ACR/ARHP Annual Meeting
Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Joan Wither¹, Stephenie Prokopec², Babak Noamani¹, Dennisse Bonilla¹, Zahi Touma³, Carmen Avila-Casado⁴, Heather Reich⁵, James Scholey⁵, Paul R. Fortin⁶, Paul Boutros² and Carolina Landolt-Marticorena¹, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Pathology, University Health Network, Toronto, ON, Canada, ⁵Nephrology, University Health Network, Toronto, ON, Canada, ⁶Université Laval, CHU de Québec, Québec, QC, Canada
Background/Purpose: The relapsing and remitting nature of lupus nephritis (LN) poses a challenge to clinicians who must balance the risk of long term kidney damage…
Abstract Number: 2863 • 2016 ACR/ARHP Annual Meeting
High Frequency of Terminally Differentiated CD8+ T Cells Characterize Systemic Lupus Erythematosus Patients with Renal Involvement
Nataly Manjarrez-Orduño¹, Laurence Menard¹, Julie Carman¹, Suzanne Suchard¹, Francesca Casano¹, Deborah Lee¹, Sium Habte¹, Sherif Daouti², Selena Kansal³, Dana Banas³, Can Jiang³, Dawn Stetsko³, Mark Cunningham³, Vivek Jayaswal⁴, Somnath Bandyopadhyay³, Sarah Hu³, Richard A. Furie⁵ and Steven G. Nadler⁶, ¹Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NY, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Biocon Bristol-Myers Squibb Research Center, Bangalore, India, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: SLE is a highly heterogeneous disease. The identification of disease subtypes with different pathological mechanisms is crucial to identify subjects with different disease progression…
Abstract Number: 1070 • 2015 ACR/ARHP Annual Meeting
CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Sarit sekhar Pattanaik¹, Aditya kumar Panda², Rashmi ranjan Sahoo¹, Rina Tripathy³ and Bidyut kumar Das¹, ¹Medicine, SCB Medical College, Cuttack, India, ²Centre for Life science, Central University of Jharkand, Ranchi, India, ³Biochemistry, SCB Medical College, Cuttack, India
Background/Purpose: Cluster of differentiation 14 (CD14) plays an important role in innate immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].